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Abstract
Background: A 49-year-old male presented with late-onset demyelinating
peripheral neuropathy, cerebellar atrophy, and cognitive deficit. Nerve biopsy
revealed intra-axonal inclusions suggestive of polyglucosan bodies, raising the
suspicion of adult polyglucosan bodies disease (OMIM 263570). Methods and
Results: While known genes associated with polyglucosan bodies storage were
negative, whole-exome sequencing identified an unreported monoallelic variant,
c.397G>T (p.Val133Phe), in the histidyl-tRNA synthetase (HARS) gene. While
we did not identify mutations in genes known to be associated with polygu-
cosan body disease, whole-exome sequencing revealed an unreported monoal-
lelic variant, c.397G>T in the histidyl-tRNA synthetase (HARS) gene, encoding
a substitution (Val133Phe) in the catalytic domain. Expression of this variant
in patient cells resulted in reduced aminoacylation activity in extracts obtained
from dermal fibroblasts, without compromising overall protein synthesis. Inter-
pretation: Genetic variants in the genes coding for the different aminoacyl-
tRNA synthases are associated with various clinical conditions. To date, a num-
ber of HARS variant have been associated with peripheral neuropathy, but not
cognitive deficits. Further studies are needed to explore why HARS mutations
confer a neuronal-specific phenotype.
Introduction
Aminoacyl-tRNA synthetases (ARSs) are a group of ubiq-
uitously expressed enzymes essential for protein synthesis.
Thirty-seven different ARSs genes exist in humans.
Among them, only three of them are functional in both
cytoplasm and mitochondria, the rest acting exclusively
either in the cytoplasm or in mitochondria.1–3 Mutations
in 33 out of the 37 ARSs genes have been implicated in a
large number of genetic disorders affecting multiple
organs and tissues, including the nervous system.3–8
Bi-allelic mutations in ARSs typically cause severe, early-
onset, recessive diseases. Most of these mutations show
loss-of-function effects but the full consequences for pro-
tein synthesis have in most cases not been assessed. In
contrast, it is still unclear if peripheral neuropathies asso-
ciated with dominant ARS mutations specifically affect
the peripheral nervous system through loss-of-function,
gain-of-function, or a combinatorial mechanism. Notably,
the vast majority of neuropathy-associated ARS alleles
exhibit loss-of-function.2,8–12 The associated phenotypic
spectrum is broad and encompasses both axonal and
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demyelinating motor and sensory neuropathies, as well as
pure motor axonal neuropathy.9,11,13
To date, five genes encoding a cytoplasmic ARS enzyme
have been implicated in autosomal dominant neuropathy,
a subgroup of the so-called Charcot-Marie-Tooth (CMT)
neuropathies.14 The reason why mono-allelic ARS muta-
tions seem to affect preferentially the nervous system
remains unclear, but may relate to the specialized process
of local translation occurring in the distal axon. These
ARSs-neuropathy-related genes are typically characterized
by a decrease in aminoacylation activity when assessed
in vivo and in vitro.2,10 Although some CMT mutations
apparently have minimal effect on the activity of the
mutant enzyme when assayed in vitro, protein synthesis
measurements in the context of a model organism (Dro-
sophila melanogaster) show a decrease nonetheless.12,15
This, in turn, raises the possibility of altered tRNA-charg-
ing having a preferential impact on the peripheral nerve
and its function during development and in adulthood.4
Among ARSs CMT genes, the histidyl-tRNA synthetase
(HARS) gene (OMIM*142810) is unique in that deleteri-
ous variants in the cytoplasmic isoform of the enzyme
can lead to autosomal dominant CMT disease (OMIM
#616625),11 but also to Usher syndrome type B3 (OMIM
*614504). In this inherited neurological syndrome, a sin-
gle HARS variant in homozygous state is reported to be
the cause of early onset of blindness and deafness.16,17 In
this report, we describe an unusual association between a
novel variant in the HARS gene and a clinical phenotype
initially suggestive of adult polyglucosan body disease
(APBD, OMIM #263570), a condition affecting both the
central and the peripheral nervous system, in an adult
individual. Our case highlights the spectrum of neurologi-
cal diseases linked to dominant and recessive ARS alleles.
Patient and Methods
Illustrative case: patient description
A 49-year old man of Spanish origin was referred to our
Nerve-Muscle Unit because of difficulty in performing
daily life activities due to slowly progressive incoordina-
tion and muscle weakness. His neonatal and pediatric his-
tory was unremarkable. A mild stuttering was noted in
adolescence and remained stable until the late 40s.
Around the age of 44, his wife noticed a “strange way of
walking”. Over the next 5 years, the patient developed
progressive leg weakness with difficulty walking and going
down the stairs. Running and playing soccer became
impossible because of leg weakness and muscle pain. At
the same time, he presented with progressive motor inco-
ordination and difficulty with manual dexterity: his hand-
writing gradually worsened, doing up buttons and
manipulating small objects became more and more cum-
bersome. At the social level, the patient became increas-
ingly withdrawn, avoiding social interaction and engaging
less in conversation as word finding and sustaining atten-
tion become laborious with time. Family history was neg-
ative for any neurologic conditions.
Neurological examination revealed moderate dysarthria
and stuttering without any other cranial nerve deficit,
moderate amyotrophy in distal lower limbs with associ-
ated mild distal muscle weakness (rated 4/5 according to
the Medical Research Council Scale), genu valgus, pes
cavus, hammer toes (Fig. 1A–C), a staggering gait, and
marked axial ataxia. Bilateral Achilles tendon areflexia
was also found. Muscle strength and deep tendon reflexes
were preserved in the trunk and upper limbs. No sensory
deficit was found.
Neuropsychological testing revealed mild to moderate
impairment of multiple cognitive functions, namely an
important attention deficit, a deficit in executive function
(frontal assessment battery score of 14/18), a slight aprax-
ia, short-term memory loss (rated using the Wechsler
Memory Scale III), and emotional blunting.
Materials, methods and results
Laboratory workup showed only increased plasma cre-
atine kinase levels (621 U/L, 25 < normal < 190). The
rest was unremarkable, including levels of vitamin B12,
B1, B6, and E. Methylmalonic acid, acylcarnitine profile,
glycosylated hemoglobin, and thyroid-stimulating hor-
mone were all within the reference range. Brain MRI was
normal with the exception of mild cerebellar atrophy
(Fig. 1D). Nerve conduction studies revealed reduced
motor nerve conduction velocities (median, ulnar, and
tibial nerves were tested bilaterally). Sensory nerve action
potential parameters and velocity were normal in all four
limbs except for the median nerve (Table 1). Amplitude
of motor responses was reduced for the peroneal and tib-
ial nerves. Median nerve distal motor latency was pro-
longed at the wrist bilaterally. These results were
consistent with a late onset demyelinating motor neu-
ropathy. Left deltoid muscle biopsy showed minor
changes with randomly distributed scattered rounded or
atrophic muscle fibers (data not shown). Sural nerve
biopsy showed periodic acid-Schiff (PAS)-positive intra-
axonal deposits suggestive of polyglucosan bodies or
focally folded myelin sheaths characteristic of CMT type
1B (Fig. 1E–G).
Based on the association of a progressive motor neu-
ropathy with cognitive difficulties and the presence of this
unusual histology of the peripheral nerve, a late-onset
form of glycogen debranching enzyme deficiency known
as APBD was supposed. However, fibroblast glycogen
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branching enzyme activity was active (0.93 lmol/min/mg
Prot, normal 0.97–1.63) making the diagnosis of APBD
unlikely. Total patient DNA was extracted using standard
procedures, for further analysis of GBE1, the APBD-asso-
ciated gene. Bidirectional Sanger sequencing of GBE1 gene
did not reveal any pathogenic variant (Laboratory for
Molecular Diseases, Lausanne University Hospital,
Switzerland). Whole-Exome Sequencing (WES) was then
carried out on Illumina HiSeq2500 sequencer, with Agi-
lent Sure Select XT Human All Exon V5 capture kit, after
appropriate informed consent. Data processing and vari-
ants annotation and filtering were made as already
described.18 We first analyzed candidate genes known to
be associated with polyglucosan bodies storage (Division
of Genetic Medicine, Lausanne University Hospital,
Switzerland). Screening of GYS1, GYG1, RBCK1, PFKM,
EPM2A, EPM2B, PRDM8, and PRKAG2 genes, first by
Sanger sequencing, and then by WES did not reveal dele-
terious variants. We then focused on all rare, nonsynony-
mous, high quality variants in the patient that were not
Figure 1. (A–G) Clinical phenotype of the patient. Genu valgus with a wide-based gait (A). Pes cavus with amyotrophy of the intrinsic foot
muscles (B–C). Coronal and sagittal T-1 and T-2 weighted brain MRI showing mild cerebellar atrophy (D). Histopathology (E–F) and electron
microscopy (G) of left sural nerve biopsy with intra-axonal inclusions suggestive of polyglucosan bodies. Shown by the arrows.
Table 1. Motor and sensory nerve conduction studies in the patient
Median motor Ulnar motor Tibial motor Median sensory Radial sensory Sural sensory
A CV A CV A CV A CV A CV A CV
R 61 26.7 8 40 0.2 28.7 22 31.6 10 47.8 11.2 48
L 51 36.6 7.7 40 0.2 33.1 – – – – – –
1Prolonged distal motor latency at 6.9 and 5.3 msec, respectively (normal < 4 msec); –: not performed; A, amplitude; CV, conduction velocity,
(normal > 49 m/sec in upper limbs; >40 m/sec in lower limbs); R, right; L, left.
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present or with a low frequency among healthy control
cohorts from the Exome Aggregation Consortium (ExAC)
database (http://exac.broadinstitute.org) and in the over-
lapping and updated genome Aggregate Database (gno-
mAD; http://gnomad.broadinstitute.org).19 The analysis
was thus reduced to only a few variants (Table S1).
Among the variants remaining after the filtering proce-
dure, we identified a heterozygote variant in the histidyl-
tRNA synthetase (HARS) gene, c.397G>T (p.Val133Phe),
not previously detected in our in-house cohort of WES
patients nor in any public database so far. This variant is
likely to be deleterious to protein function as it affects a
highly conserved amino acid present in the catalytic domain
of the protein, as do the other reported pathogenic neu-
ropathy variants (Fig. 2A–C). It is predicted to be deleteri-
ous by various in silico software programs (CADD,20
VEST3,21 MutationTaster (http://www.mutationtaster.org/)
and SIFT (http://sift.jcvi.org/). It clusters with other known
pathogenic variants in a small region of the protein
(Fig. 2A–B). The variant was then confirmed by Sanger
sequencing in the patient and shown to be absent in mater-
nal DNA (paternal DNA was not available). Although the
variant is located in the consensus acceptor splice site of
exon 5, in-silico predictive software does not predict a
major impact on splicing, similarly to the other surround-
ing known pathogenic HARS variants (Fig. 2B).
The p.V133F substitution associated with this mutation
is located within the HARS catalytic domain, on helix a3
in the active site. This location is proximal to seven dif-
ferent substitutions that have previously been linked to
CMT(Fig. 3A–B). With respect to primary sequence,
Val133 lies between Thr132 and Pro134. Previously, the
p.T132I and p.P134H substitutions were linked to
CMT in well-characterized families, each with multiple
Figure 2. (A–C) Localization of reported pathogenic HARS variants on its protein domains. In orange, variants associated with Charcot-Marie-
Tooth disease11 and in green with Usher syndrome.16,17 In red, localization of our newly discovered variant (A). HARS cDNA sequence around our
newly discovered variant (B). Alignment of HARS sequences from distantly related genera. p.Val133Phe (V133F) is strictly conserved among all
eukaryotes, and replaced by a smaller residue (Alanine) in E. coli (C).
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subjects.11 Of note, several of the CMT patients with
these mutations had late onset of the disease, like our
case.10 In addition, three-dimensional modeling suggests
that the V133F substitution introduces a steric clash with
the nearby residue Tyr330, potentially altering its interac-
tions with histidine. Valine 133 is strictly conserved in
eukaryotes, and is replaced by alanine in E. coli, high-
lighting the likely steric constraints at this position. The
p.Y330C substitution is also linked to CMT, and the sub-
stitution decreases the kcat/KM(ATP) for aminoacylation by
~500-fold.2 Based on the proximity of V133F to these
other CMT-associated mutants, the substitution is likely
to be pathogenic.
While the seven previously characterized HARS CMT
variants display a loss-of-function effect in yeast and/or
cell-free enzymatic assays,2,11 the aminoacylation func-
tion of these ARS-CMT variants has not been directly
assessed in patient cells. Using a previously described
method,22 we examined aminoacylation activity directly
in cell lysates collected from V133F patient fibroblasts.
We observed that the rate of tRNAHis aminoacylation
was significantly reduced (~25%) in patient cell lysates,
relative to extracts obtained from control fibroblasts
(Fig. 4). The reduction in HARS activity was not associ-
ated with altered protein expression, as determined by
western blotting and immunofluorescence imaging
(Fig. 5). Furthermore, HARS protein localized to the
cytoplasm with a slight perinuclear enrichment in both
control and patient cells (Fig. 5). Using the OPP-
puromycin labeling assay,23 we found that the rate of
protein synthesis was similar in control and patient
fibroblasts (Fig. 6), which is unsurprising given the tis-
sue-specific phenotype observed.
Discussion
The association of late onset motor neuropathy, cognitive
dysfunction, and the presence of rare intra-axonal inclu-
sions in nerve biopsy initially suggested a diagnosis of
APBD. Instead of a genetic defect in one of the candidate
genes related to polyglucosan storage diseases, WES
revealed an unreported variant in the HARS gene, namely
c.397G>T (p.Val133Phe). The following observations sup-
port its role in the pathogenesis of the clinical picture in
our patient. Firstly, the variant is extremely rare, consis-
tent with other pathogenic ARS variants associated with
CMT. Secondly, the affected residue is situated proximal
to other active site residues abutting the histidine-binding
site which have previously been shown to cause CMT.2,11
Thirdly, the mutation was shown to reduce histidine-
specific aminoacylation in cells, despite the retention of
wild-type HARS levels in patient cells (Fig. 5). Interest-
ingly, the ~25% decrease in aminoacylation associated
with the dominant negative mutation did not reduce
overall protein synthesis, as measured by the puromycin
click-chemistry assay (Fig. 6). These results are consistent
with a scenario in which the aminoacylation decreases
linked to ARS CMT mutations specifically impact
Figure 3. (A–B) Location of the peripheral neuropathy-associated substitution V133F in the active site of human histidyl-tRNA synthetase (HARS).
Histidyl-tRNA synthetase (PDB 4PHC) is shown as a dimer in ribbon cartoon representation with the first monomer in green and the second
monomer in cyan. Neuropathy-associated HARS residues are shown in the 3D structure in stick representation where substitutions reported in
Brozkova et al. are shown in yellow, those reported in Abbott et al. are shown in cyan, and the substitution reported here is shown in salmon2,11
(A). Modeling of the p.Val133Phe (V133F) substitution (van der Waals radius in dot representation) indicates steric clash with Tyr107, Lys106, and
Tyr330, all depicted in CPK space filling representation. Note that Y330C is one of the substitutions associated with Charcot–Marie tooth
syndrome, as described in Abbott et al..2 In this modeling depiction, the resulting structure was not subjected to energy minimization, which
would likely produce local side chain rearrangements (B).
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specialized tissues with high protein synthesis demands
(i.e. neurons), but not cells that may only require a
“housekeeping” level of protein synthesis. Interestingly,
mere haploinsufficiency of a given ARS allele does not
lead to disease.24,25 Accordingly, future studies including
segregation and additional functional studies in neurons
will help in defining the pathogenic role of this HARS
gene variant in inherited neuropathy.
Only a small number of pathogenic missense variants in
the HARS gene have been reported, and the one detected in
our patient maps in close proximity to the seven that have
been characterized in detail (Figs. 2 and 3A).10,11 All are
presumed to have an impact on aminoacylation function,
and all have been associated with peripheral neuropathy.
However, no cognitive deficit like the one present in our
patient, nor PAS positive (“polyglucosan”) inclusions in
nerve biopsy have been reported in HARS-related neuropa-
thy patients so far. As inclusion bodies may be observed in
the nerves of healthy individuals in rare instances, in partic-
ular in the elderly, without clinical consequences,26 it can-
not be excluded that this feature may in fact be unrelated to
the neuropathy.
Next generation sequencing has showed us that indi-
viduals bearing two or more genetic conditions are not
rare; and that the distinct conditions may interact to form
a more complex phenotype.27,28 While the principle of
looking for a unifying diagnosis remains valid, physicians
should consider the possibility of multiple coexisting
diagnoses. This is particularly valid in cases where clinical
features are difficult to be explained by a single diagnosis.
In our case and despite a thorough molecular analysis, no
co-existing diagnosis explaining the entire clinical spec-
trum was identified.
The first report of disease-causing variant in an ARS
gene was published in 2003.29 Since then, an increasing
number of phenotype–genotype associations have been
reported.3,4 Surprisingly, many of these genetic defects are
associated with diseases of the nervous system, including
encephalopathy, cerebellar ataxia, and peripheral neuropa-
thy. This data underlines the importance of ARSs in neu-
ronal development and function and suggests that a
broader set of ARSs genes may play an important role in
inherited neurological diseases.
However, it remains to be determined whether HARS
deleterious variants are more pleiotropic than hitherto
assumed and that their clinical expression may include
PAS-positive intra-axonal inclusions and/or involvement
of the central nervous system. Recruitment of more
Figure 4. Analysis of HARS activity in control and V133F patient dermal fibroblasts. HARS activity in cell extracts was determined by calculating
the slope of product formed over time. Activity was significantly reduced (~25%) in V133F patient cells. Data are displayed as mean  SEM
(n = 3). * indicates P < 0.05 by two-tailed unpaired t-test
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 1077
B. Royer-Bertrand et al. Atypical HARS-Related Peripheral Neuropathy
Figure 5. (A–D) HARS western blotting and immunofluorescence microscopy in control and V133F patient dermal fibroblasts. Expression of HARS
at the protein level is similar in control and V133F patient cells as determined by western blotting (A, B) and immunofluorescence imaging (C, D).
HARS protein localizes primarily perinuclearly, and throughout the cytoplasm in both control and patient cells (C). Data are displayed as
mean  SEM (western blot n = 3; imaging n = 48 control cells, 52 patient cells). Scale bar = 50 lm.
Figure 6. OPP-puromycin/click-chemistry labeling assay of protein synthesis rate. Rate of protein synthesis as determined by OPP-puromycin
fluorescence intensity is unaltered in V133F patient fibroblasts (A, B). Data are displayed as mean  SEM (n = 47 control cells, 40 patient cells).
Scale bar = 50 lm.
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patients with HARS variants and functional studies to
predict their pathogenicity are necessary to better define
the HARS gene and its impact on the phenotypic expres-
sion.
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